Compugen Ltd (CGEN)

Feb 18, 2025

Compugen Ltd. Sets Date for Q4 2024 Financial Results Announcement - TipRanks

Feb 18, 2025

Feb 18, 2025

Earnings Alert: Compugen Sets Date for Critical Year-End Financial Report & Strategic Update - StockTitan

Feb 18, 2025

Feb 18, 2025

Compugen: Immuno-Oncology Innovator Poised For A Comeback (NASDAQ:CGEN) - Seeking Alpha

Feb 18, 2025

Feb 18, 2025

Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average – Time to Sell? - Defense World

Feb 18, 2025

Feb 15, 2025

Compugen Updates Filing Structure with Bristol Myers Squibb - TipRanks

Feb 15, 2025

Feb 13, 2025

Computational Biology Market to Generate $9.52 Billion in Revenues in 2025; Forecast to Reach $22.47 Billion by 2029Analysis of the Key Drivers, Top Segments, Regional Shifts, Leading Players & More - Yahoo Finance

Feb 13, 2025

Feb 13, 2025

Financial Comparison: Compugen (NASDAQ:CGEN) & Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World

Feb 13, 2025

Feb 11, 2025

CGEN’s Q2 earnings predictions: What the experts say - US Post News

Feb 11, 2025

Feb 08, 2025

Compugen Ltd (NASDAQ: CGEN) Has Decreased By 14.22 Percent This Year. Is It A Better Buy Than Others? - Marketing Sentinel

Feb 08, 2025

Feb 06, 2025

JPMorgan Chase & Co. Has $122,000 Stock Holdings in Compugen Ltd. (NASDAQ:CGEN) - MarketBeat

Feb 06, 2025

Feb 06, 2025

Views of Wall Street’s Leading Experts on Compugen Ltd - SETE News

Feb 06, 2025

Feb 06, 2025

The Psychology of Compugen Ltd Inc. (CGEN) Price Performance: Understanding Market Sentiment - The InvestChronicle

Feb 06, 2025

Feb 06, 2025

Insider’s View: Deciphering Compugen Ltd (CGEN)’s Financial Health Through Ratios - The Dwinnex

Feb 06, 2025

Feb 04, 2025

Investing in Compugen Ltd (CGEN) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Feb 04, 2025

Feb 04, 2025

Major Cancer Immunotherapy Breakthrough Could Be Unveiled at Oppenheimer Conference - StockTitan

Feb 04, 2025

Feb 03, 2025

JPMorgan Chase & Co. Has $122,000 Holdings in Compugen Ltd. (NASDAQ:CGEN) - Defense World

Feb 03, 2025

Feb 01, 2025

Compugen (NASDAQ:CGEN) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat

Feb 01, 2025

Jan 30, 2025

CGENCompugen Ltd Latest Stock News & Market Updates - StockTitan

Jan 30, 2025

Jan 21, 2025

Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025

Jan 21, 2025

Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Jan 21, 2025

Jan 14, 2025

Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - Simply Wall St

Jan 14, 2025

Jan 14, 2025

Compugen (NASDAQ:CGEN) Now Covered by Oppenheimer - Defense World

Jan 14, 2025

Jan 13, 2025

Compugen Ltd (NASDAQ: CGEN) Gains 3.14% In Early Trade; What Lies Ahead? - Stocks Register

Jan 13, 2025

Jan 13, 2025

Oppenheimer Initiates Coverage on Compugen (NASDAQ:CGEN) - MarketBeat

Jan 13, 2025

Jan 13, 2025

Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential By Investing.com - Investing.com Australia

Jan 13, 2025

Jan 13, 2025

Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential - Investing.com India

Jan 13, 2025

Jan 08, 2025

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Compugen Launches First-in-Class Cancer Trial with Novel IL-18 Antibody COM503 - StockTitan

Jan 08, 2025

Jan 01, 2025

Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy - AOL

Jan 01, 2025

Dec 26, 2024

The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable - Yahoo Finance

Dec 26, 2024

Dec 11, 2024

Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail

Dec 11, 2024

Dec 11, 2024

Gilead Sciences Inc (GILD-Q) QuotePress Release - The Globe and Mail

Dec 11, 2024

Dec 06, 2024

Compugen (CGEN) Stock Surges Amid Biotech Industry Movement - GuruFocus.com

Dec 06, 2024

Nov 30, 2024

Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World

Nov 30, 2024

Nov 27, 2024

Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks

Nov 27, 2024

Nov 27, 2024

Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan

Nov 27, 2024

Nov 24, 2024

Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World

Nov 24, 2024

Nov 22, 2024

Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com

Nov 22, 2024

Nov 16, 2024

Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat

Nov 16, 2024

Nov 15, 2024

Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Nov 13, 2024

Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... - Yahoo Finance

Nov 13, 2024

Nov 13, 2024

Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... By GuruFocus - Investing.com Canada

Nov 13, 2024

Nov 12, 2024

Compugen Reports Strong Q3 2024 Results and Progress - TipRanks

Nov 12, 2024

Nov 12, 2024

Compugen: Q3 Earnings Snapshot - The Washington Post

Nov 12, 2024

Nov 12, 2024

Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates - Yahoo Canada Finance

Nov 12, 2024